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Introduction: Cytotoxic agents have immunomodulatory
effects, providing a rationale for combining atezolizumab
(anti-programmed death-ligand 1 [anti–PD-L1]) with
chemotherapy. The randomized phase III IMpower131
study (NCT02367794) evaluated atezolizumab with
platinum-based chemotherapy in stage IV squamous NSCLC.
Methods: A total of 1021 patients were randomized 1:1:1
to receive atezolizumabþcarboplatinþpaclitaxel (AþCP)
(n ¼ 338), atezolizumabþcarboplatinþnab-paclitaxel
(AþCnP) (n ¼ 343), or carboplatinþnab-paclitaxel (CnP)
(n ¼ 340) for four or six 21-day cycles; patients randomized
to the AþCP or AþCnP arms received atezolizumab main-
tenance therapy until progressive disease or loss of clinical
benefit. The coprimary end points were investigator-
assessed progression-free survival (PFS) and overall sur-
vival (OS) in the intention-to-treat (ITT) population. The
secondary end points included PFS and OS in PD-L1 sub-
groups and safety. The primary PFS (January 22, 2018) and
final OS (October 3, 2018) for AþCnP versus CnP are
reported.
Results: PFS improvement with AþCnP versus CnP was
seen in the ITT population (median, 6.3 versus 5.6 mo;
hazard ratio [HR] ¼ 0.71, 95% confidence interval [CI]:
0.60–0.85; p ¼ 0.0001). Median OS in the ITT population
was 14.2 and 13.5 months in the AþCnP and CnP arms
(HR ¼ 0.88, 95% CI: 0.73–1.05; p ¼ 0.16), not reaching
statistical significance. OS improvement with AþCnP versus
CnP was observed in the PD-L1–high subgroup (HR ¼ 0.48,
95% CI: 0.29–0.81), despite not being formally tested.
Treatment-related grade 3 and 4 adverse events and serious
adverse events occurred in 68.0% and 47.9% (AþCnP) and
57.5% and 28.7% (CnP) of patients, respectively.
Conclusions: Adding atezolizumab to platinum-based
chemotherapy significantly improved PFS in patients with
first-line squamous NSCLC; OS was similar between the
arms.
 2020 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Squamous NSCLC; Atezolizumab; Nab-paclitaxel;
Carboplatin; IMpower131Introduction
Platinum-based chemotherapy remains a first-line
treatment option for many patients with advanced
squamous NSCLC, which accounts for 25% to 30% of
lung cancers.1-3 Nevertheless, these treatment options
provide limited efficacy, with a median overall survival
(OS) of less than 1 year.3 More recently, the introductionof pembrolizumab to platinum-based chemotherapy for
the first-line treatment of patients with metastatic
squamous NSCLC has led to significant improvement in
OS, with a median of 15.9 months.4 In patients with
programmed death-ligand 1 (PD-L1) expression on
greater than or equal to 1% of tumor cells (TCs), pem-
brolizumab monotherapy has resulted in significant OS
improvement compared to that observed with platinum-
based chemotherapy,5 representing a chemotherapy-free
treatment option.
A significant OS benefit with atezolizumab (anti–PD-
L1 antibody) versus docetaxel was reported in patients
with previously treated NSCLC, regardless of PD-L1
expression or tumor histology.6 On the basis of these
and other data, atezolizumab monotherapy was
approved for patients with metastatic NSCLC that pro-
gressed during or after platinum-based chemotherapy.7,8
In the first-line setting, atezolizumab monotherapy has
resulted in significant OS improvement compared to that
observed with platinum-based chemotherapy in patients
with high PD-L1 levels (50% TCs or 10% tumor-
infiltrating immune cells [ICs]) independent of tumor
histology.9
Cytotoxic agents can exhibit positive immunomodu-
latory effects by releasing high levels of tumor antigens
and reinstating immunosurveillance, suggesting that
chemotherapy may enhance atezolizumab’s antitumor
activity.10 The phase III IMpower130 study reported that
the addition of atezolizumab to carboplatin and nab-
paclitaxel for the first-line treatment of patients with
metastatic nonsquamous NSCLC provided a clinically
meaningful and statistically significant benefit in OS and
progression-free survival (PFS) versus chemotherapy
alone; thus, this atezolizumab regimen received approval
in the United States and the European Union.11-13
Furthermore, in the IMpower150 study, the addition of
atezolizumab to bevacizumab, carboplatin, and paclitaxel
for the first-line treatment of patients with metastatic
nonsquamous NSCLC provided significant improvements
in PFS and OS, resulting in the approval of the regimen in
this patient population.14,15 Here, the efficacy and safety
from the phase III IMpower131 study (NCT02367794),
which evaluated the combination of atezolizumab and
carboplatin-taxane doublet chemotherapy as first-line
therapy in patients with stage IV squamous NSCLC, are
reported.Materials and Methods
Study Design and Treatment
In the global, open-label, phase III IMpower131
study, the patients were randomized 1:1:1 to receive
atezolizumabþcarboplatinþpaclitaxel (AþCP),
atezolizumabþcarboplatinþnab-paclitaxel (AþCnP), or
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were sex (male or female), presence of liver metastases
(yes or no), and PD-L1 expression by immunohisto-
chemistry (TC3 and any IC versus TC0/1/2 and IC2/3
versus TC0/1/2 and IC0/1). The patients received four
or six 21-day cycles of induction treatment (number of
cycles per investigator discretion, chosen before therapy
initiation). Atezolizumab was administered at 1200 mg
intravenously (IV; day 1), carboplatin at an area under
the concentrationtime curve of 6 mg/mL/min IV (day
1), paclitaxel at 200 mg/m2 IV (175 mg/m2 for Asian
race/ethnicity; day 1), and nab-paclitaxel at 100 mg/m2
IV (days 1, 8, and 15). After induction, patients in the
AþCP and AþCnP arms continued atezolizumab until
disease progression per the Response Evaluation Criteria
in Solid Tumors (RECIST) version 1.1 or loss of clinical
benefit. Crossover to atezolizumab was not allowed.
Patient Criteria
Eligible patients had histologically or cytologically
confirmed stage IV squamous NSCLC per the seventh
edition of the American Joint Committee on Cancer/
Union for International Cancer Control TNM Staging
system,16 had not received chemotherapy for stage IV
squamous NSCLC, had measurable disease per the
RECIST version 1.1, had a baseline Eastern Cooperative
Oncology Group (ECOG) performance status (PS) of 0 or
1, and had tumor tissue available for central PD-L1
testing. Patients known to have EGFR mutations or ALK
fusion oncogene were eligible for the study but had to
have experienced disease progression on or intolerance
to one or more approved tyrosine kinases or ALK in-
hibitors, respectively; testing for EGFR and ALK status
was not mandated. Exclusion criteria included active or
untreated central nervous system metastases; history of
autoimmune disease; previous immune checkpoint
blockade therapies with the exception of anti–CTLA-4
therapy, provided the last dose was given more than or
equal to 6 weeks before randomization; and systemic
immunosuppressive medications less than 2 weeks
before randomization.
End Points and Assessments
The coprimary end points were investigator-assessed
PFS per the RECIST version 1.1 and OS in the intention-
to-treat (ITT) population. The secondary end points
included investigator-assessed objective response rate
(ORR), duration of response (DOR), PFS, and OS evalu-
ated in PD-L1 subgroups (defined as TC2/3 or IC2/3 and
TC1/2/3 or IC1/2/3) and in the T-effector (Teff) popu-
lation. Additional PD-L1 subpopulations were explored:
TC3 or IC3 (high expression), TC1/2 or IC1/2 (lowexpression), and TC0 and IC0 (negative). Baseline PD-L1
tumor expression was evaluated in archival tissue or
tissue obtained from a biopsy at screening using the
SP142 PD-L1 immunohistochemistry assay (Ventana
Medical Systems, Inc., Tucson, AZ) and was scored by a
central laboratory, as previously described6
(Supplementary Table 1). The Teff gene signature was
defined by the average expression of CD274, CXCL9, and
IFNg in RNA isolated from tumor tissue and was
measured using quantitative real-time polymerase chain
reaction relative to the expression of a control gene
(Roche Molecular Systems, Pleasanton, CA). The Teff
population was defined as patients in the ITT population
with a Teff signature score greater than or equal
to 1.91.
The safety and tolerability of the study treatment
were evaluated, and adverse events (AEs) were assessed
per the National Cancer Institute Common Terminology
Criteria for AEs version 4.0. Tumor assessments were
performed at baseline, every 6 weeks for the first 48
weeks after cycle 1, day 1, and every 9 weeks thereafter
until disease progression per the RECIST version 1.1 or
loss of clinical benefit for patients who continued ate-
zolizumab after initial disease progression.Statistical Analysis
The coprimary end points of PFS and OS in the ITT
population were tested first between the AþCnP and
CnP arms (Supplementary Fig. 2). To control the type I
error rate at 0.05 (two-sided), the alpha was split and a
two-sided alpha of 0.006 and 0.044 was allocated to PFS
and OS, respectively. If PFS was statistically significant,
the alpha would be recycled, and OS would be tested at a
two-sided significance level of 0.05. Only if OS between
the AþCnP and CnP arms was statistically significant
would PFS and OS be tested with alpha allocation be-
tween the AþCP and CnP arms (Supplementary Fig. 8). At
the time of the primary PFS analysis, the first planned
interim analysis of OS was performed. For the first interim
analysis of OS, a nominal alpha (0.0001) was spent.
Stratified log-rank tests were used for treatment
comparisons of PFS and OS, using the same stratification
factors as those for randomization (sex, baseline liver
metastases, and PD-L1 status). Kaplan-Meier methodol-
ogy was used to estimate median PFS and median OS for
each treatment arm. Brookmeyer-Crowley methodology
was used to calculate 95% confidence intervals (CIs) for
the medians. A stratified Cox regression model was used
to estimate hazard ratios (HRs). Analyses of prespecified
subgroups were performed using unstratified HRs esti-
mated from Cox proportional hazard models and Kaplan-
Meier estimates.
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A total of 1021 patients were enrolled at 317 study
sites across 26 countries between June 2015 and March
2017 and comprised the ITT population. Patients were
randomized 1:1:1 to receive AþCP (n ¼ 338), AþCnP
(n ¼ 343), or CnP (n ¼ 340) (Supplementary Fig. 1). The
clinical cutoff date (CCOD) was January 22, 2018, for the
primary PFS analysis and October 3, 2018, for the final
OS analysis. Overall, 82% of patients (n ¼ 835) were
male, 92% (n ¼ 935) were current or previous smokers,
33% (n ¼ 334) had a baseline ECOG PS of 0, and 67%
(n ¼ 685) had a baseline ECOG PS of 1 (Table 1). The
median age was 65 years (range, 23–86). One patient in
the AþCnP arm had an EGFR mutation; for all other
patients, the EGFR mutation and ALK rearrangement
status were either negative or unknown. In the AþCP
arm, 48 (14.2%), 120 (35.5%), and 170 patients (50.3%)
had tumors with high (TC3 or IC3), low (TC1/2 or IC1/
2), and negative (TC0 and IC0) PD-L1 expression,
respectively. A total of 47 (13.7%), 136 (39.7%), and 160
patients (46.6%) in the AþCnP arm and 44 (12.9%), 125
(36.8%), and 171 patients (50.3%) in the CnP arm had
tumors with high, low, and negative PD-L1 expression,
respectively.
PFS Analysis
At primary CCOD (January 22, 2018), median follow-
up was 18.1 months in the AþCnP arm and 16.1 months
in the CnP arm. In the ITT population, 270 patients
(78.7%) in the AþCnP arm and 289 patients (85.0%) in
the CnP arm had a PFS event per investigator assess-
ment. PFS benefit was found with AþCnP versus CnP in
the ITT population (stratified HR ¼ 0.71, 95% CI: 0.60–
0.85; p ¼ 0.0001) (Fig. 1A), with a median PFS of 6.3months (95% CI: 5.7–7.1) in the AþCnP arm and 5.6
months (95% CI: 5.5–5.7) in the CnP arm. The 12-month
PFS rate was 24.7% in the AþCnP arm versus 12.0% in
the CnP arm. The PFS in the clinical subgroups within the
ITT population is reported in Supplementary Figure 3.
The PFS according to PD-L1 expression status and Teff
gene signature is presented in Table 2. Although the PFS
in the PD-L1 expression subgroups was not formally
tested, patients whose tumors had the highest PD-L1
expression level (TC3 or IC3) had a more pronounced
benefit with AþCnP than those treated with CnP did
(median PFS was 10.1 versus 5.1 mo in the AþCnP
versus CnP arms; HR ¼ 0.41; 95% CI: 0.25–0.68). PFS in
the ITT population assessed by an independent review
facility resulted in a median PFS of 6.9 months in the
AþCnP arm and 5.7 months in the CnP arm (stratified
HR ¼ 0.80, 95% CI: 0.67–0.96) (Supplementary Fig. 5).
Updated investigator-assessed PFS for the ITT popula-
tion with a CCOD of October 3, 2018, is shown in the
supplementary data (Supplementary Fig. 6).OS Analysis
At the final OS analysis (CCOD: October 3, 2018),
median follow-up was 26.8 months in the AþCnP arm
and 24.8 months in the CnP arm. There were 228
(66.5%) and 245 (72.1%) deaths in the AþCnP and CnP
arms, respectively. Median OS in the ITT population was
similar between the AþCnP and CnP arms: 14.2 months
(95% CI: 12.3–16.8) and 13.5 months (95% CI: 12.2–
15.1), respectively (stratified HR ¼ 0.88, 95% CI: 0.73–
1.05; p ¼ 0.1581) (Fig. 1B, Supplementary Fig. 4). At 24
months, 32.5% and 26.6% of patients in the AþCnP and
CnP arms, respectively, were alive. OS in the clinical
subgroups within the ITT population is reported in
Supplementary Figure 4. OS according to PD-L1
expression status and Teff gene signature is presented
in Table 3. In the high PD-L1 expression subgroup (TC3
or IC3), median OS was 23.4 months in the AþCnP arm
versus 10.2 months in the CnP arm (HR ¼ 0.48, 95% CI:
0.29–0.81) (Table 3). As the OS boundary for significance
was not crossed between the AþCnP and CnP arms in
the ITT population, PFS and OS were not formally tested
between the AþCP and CnP arms.
After discontinuation of study treatment, 124 pa-
tients (36.2%) in the AþCnP arm and 198 patients
(58.2%) in the CnP arm received subsequent anticancer
therapies (Supplementary Table 2). In the AþCnP arm,
110 patients (32.1%) received subsequent chemo-
therapy and 22 patients (6.4%) received subsequent
cancer immunotherapy. In the CnP arm, 93 patients
(27.4%) received subsequent chemotherapy and 147
patients (43.2%) received subsequent cancer
Table 1. Baseline Demographics and Characteristics of the ITT Populationa
Characteristic
ITT
AþCP (n ¼ 338) AþCnP (n ¼ 343) CnP (n ¼ 340)
Median age (range), y 66 (43–85) 65 (23–83) 65 (38–86)
Age groups (y), n (%)
<65 150 (44.4) 170 (49.6) 156 (45.9)
65–74 148 (43.8) 134 (39.1) 145 (42.6)
75–84 39 (11.5) 39 (11.4) 38 (11.2)
85 1 (0.3) 0 1 (0.3)
Male, n (%) 278 (82.2) 280 (81.6) 277 (81.5)
Liver metastases present at enrollment (IxRS), n (%) 66 (19.5) 70 (20.4) 69 (20.3)
Ethnic origin, n (%)
White 290 (85.8) 289 (84.3) 290 (85.3)
Asian 34 (10.1) 41 (12.0) 37 (10.9)
Black or African American 3 (0.9) 4 (1.2) 7 (2.1)
American Indian or Alaska Native 3 (0.9) 1 (0.3) 1 (0.3)
Native Hawaiian or other Pacific Islander 1 (0.3) 0 0
Multiple 1 (0.3) 6 (1.7) 1 (0.3)
Unknown 6 (1.8) 2 (0.6) 4 (1.2)
ECOG PS, n (%)
0 109 (32.2) 115 (33.5) 110 (32.4)
1 229 (67.8) 227 (66.2) 229 (67.4)
Unknown 0 1 (0.3) 1 (0.3)
Tobacco use history, n (%)
Never smoker 30 (8.9) 32 (9.3) 23 (6.8)
Current or previous smoker 308 (91.1) 311 (90.7) 316 (92.9)
Unknown 0 0 1 (0.3)
Teff populations, n (%)b
Low 185 (54.7) 189 (55.1) 175 (51.5)
High 123 (36.4) 124 (36.2) 147 (43.2)
Unknown 30 (8.9) 30 (8.7) 18 (5.3)
PD-L1 expression subgroups, n (%)c
TC3 or IC3 48 (14.2) 47 (13.7) 44 (12.9)
TC2/3 or IC2/3 100 (29.6) 115 (33.5) 108 (31.8)
TC 1/2/3 or IC1/2/3 167 (49.4) 182 (53.1) 169 (49.7)
TC1/2 or IC1/2 120 (35.5) 136 (39.7) 125 (36.8)
TC0 and IC0 170 (50.3) 160 (46.6) 171 (50.3)
aCCOD: October 03, 2018.
bTeff high, T-effector signature score greater than or equal to 1.91; Teff low, T-effector signature score less than 1.91.
cTC3 or IC3 (high) ¼ PD-L1 expression on greater than or equal to 50% of TC or greater than or equal to 10% of IC; TC2/3 or IC2/3 ¼ PD-L1 expression on greater
than or equal to 5% of TC or IC; TC1/2/3 or IC1/2/3 (positive) ¼ PD-L1 expression on greater than or equal to 1% of TC or IC; TC1/2 or IC1/2 (low) ¼ PD-L1
expression on greater than or equal to 1% of TC or IC and less than 50% of TC and less than 10% of IC; TC0 and IC0 (negative) ¼ PD-L1 expression on less than 1%
of TC and IC.
AþCnP, atezolizumabþcarboplatinþnab-paclitaxel; AþCP, atezolizumabþcarboplatinþpaclitaxel; CCOD, clinical cutoff date; CnP, carboplatinþnab-
paclitaxel; ECOG PS, Eastern Cooperative Oncology Group performance status; IC, tumor-infiltrating immune cells; ITT, intention-to-treat; PD-L1, pro-
grammed death-ligand 1; Teff, T-effector; TC, tumor cells.
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frequently administered cancer immunotherapy after
the end of study treatment (Supplementary Table 2).
OS data from the first (CCOD: January 22, 2018) and
second (CCOD: April 20, 2018) interim analyses are
included in the supplementary data (Supplementary
Figs. 7 and 8).
ORR and DOR
At the final CCOD (October 3, 2018), confirmed
investigator-assessed ORR in the ITT population was49.7% in the AþCnP arm and 41.0% in the CnP arm,
with a median DOR of 7.3 months (95% CI: 6.8–9.5) and
5.2 months (95% CI: 4.4–5.6), respectively
(Supplementary Table 3). A total of 37 patients (21.8%)
in the AþCnP arm and 16 patients (11.5%) in the CnP
arm had ongoing responses at the time of clinical cutoff.
Overall, ORR and DOR at the final analysis were consis-
tent with those from the primary analysis17 (January 22,
2018). In the subgroup of patients with high PD-L1
expression (TC3 or IC3), ORR was 61.7% with AþCnP
and 31.8% with CnP, and median DOR was 13.6 and 5.5
Figure 1. Investigator-assessed PFS and OS in the ITT population. (A) Kaplan-Meier estimates of PFS at the primary analysis
(CCOD: January 22, 2018). (B) Kaplan-Meier estimates of OS at the final analysis (CCOD: October 3, 2018). AþCnP, atezoli-
zumabþcarboplatinþnab-paclitaxel; CCOD, clinical cutoff date; CnP, carboplatinþnab-paclitaxel; ITT, intention-to-treat;
OS, overall survival; PFS, progression-free survival.
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PD-L1–low (TC1/2 or IC1/2) and PD-L1–negative (TC0
and IC0) subgroups, ORR was 52.6% with AþCnP and
43.5% with CnP and 43.8% with AþCnP and 41.5% with
CnP, respectively.
Safety
A total of 332 patients in the AþCP arm and 334
patients each in the AþCnP and CnP arms had received
any amount of study treatment and were included in the
safety population. At the time of the final CCOD (October
3, 2018), the median treatment duration of atezolizumab
was 5.5 months (range, 0–37) in the AþCP arm, with a
median of eight cycles (range, 1–55), and 6.7 months
(range, 0–37) in the AþCnP arm, with a median of 10
cycles (range, 1–51). Median carboplatin treatment
duration was 2.2 months (range, 0–5) in the AþCP arm,2.6 months (range, 0–7) in the AþCnP arm, and 2.4
months (range, 0–7) in the CnP arm. For nab-paclitaxel,
the median duration of treatment was 3.0 months
(range, 0–7) in the AþCnP arm and 2.8 months (range,
0–7) in the CnP arm. Median treatment duration of
paclitaxel in the AþCP arm was 2.2 months (range, 0–5).
Any-cause AEs of any grade occurred in 325 patients
(97.9%) in the AþCP arm, 332 patients (99.4%) in the
AþCnP arm, and 324 patients (97.0%) in the CnP arm
(Table 4). Any-cause serious AEs occurred in 143 pa-
tients (43.1%) in the AþCP arm, 160 patients (47.9%) in
AþCnP arm, and 96 patients (28.7%) in the CnP arm. A
total of 28 patients (8.4%) in the AþCP arm, 34 patients
(10.2%) in the AþCnP arm, and 14 patients (4.2%) in
the CnP arm had a grade 5 AE of any cause. The higher
incidence of serious AEs observed in the atezolizumab-
containing arms was mainly driven by respiratory,
Table 2. Investigator-Assessed PFS Among Biomarker
Subgroups in the ITT Population at Primary Analysisa
Median PFS
(mo)
HR (95% CI)Subgroup AþCnP CnP
Teff populationsb
Teff high 6.9 5.6 0.61 (0.46–0.81)
Teff low 6.0 5.7 0.84 (0.67–1.05)
PD-L1 subgroupsc
TC3 or IC3 10.1 5.1 0.41 (0.25–0.68)
TC2/3 or IC2/3 8.4 5.6 0.53 (0.39–0.72)
TC1/2/3 or IC1/2/3 7.1 5.6 0.61 (0.48–0.77)
TC1/2 or IC1/2 6.5 5.6 0.70 (0.54–0.91)
TC0 and IC0 5.7 5.6 0.82 (0.65–1.04)
aCCOD: January 22, 2018.
bTeff high, T-effector signature score greater than or equal to 1.91; Teff
low, T-effector signature score less than 1.91.
cTC3 or IC3 (high) ¼ PD-L1 expression on greater than or equal to 50% of TC
or greater than or equal to 10% of IC; TC2/3 or IC2/3 ¼ PD-L1 expression on
greater than or equal to 5% of TC or IC; TC1/2/3 or IC1/2/3 (positive) ¼ PD-
L1 expression on greater than or equal to 1% of TC or IC; TC1/2 or IC1/2
(low) ¼ PD-L1 expression on greater than or equal to 1% of TC or IC and less
than 50% of TC and less than 10% of IC; TC0 and IC0 (negative) ¼ PD-L1
expression on less than 1% of TC and IC.
AþCnP, atezolizumabþcarboplatinþnab-paclitaxel; CCOD, clinical cutoff
date; CI, confidence interval; CnP, carboplatinþnab-paclitaxel; HR, hazard
ratio; IC, tumor-infiltrating immune cells; ITT, intention-to-treat; PD-L1,
programmed death-ligand 1; PFS, progression-free survival; TC, tumor cells;
Teff, T-effector.
Table 3. OS in Biomarker Subgroups in the ITT Population at
Final Analysisa
Median OS (mo)
HR (95% CI)Subgroup AþCnP CnP
Teff populationsb
Teff high 17.0 15.9 0.88 (0.66–1.19)
Teff low 13.2 12.6 0.89 (0.69–1.13)
PD-L1 subgroupsc
TC3 or IC3 23.4 10.2 0.48 (0.29–0.81)
TC2/3 or IC2/3 20.4 14.5 0.72 (0.52–1.00)
TC1/2/3 or IC1/2/3 14.8 15.0 0.86 (0.67–1.11)
TC1/2 or IC1/2 12.8 15.5 1.08 (0.81–1.45)
TC0 and IC0 14.0 12.5 0.87 (0.67–1.13)
aCCOD: October 3, 2018.
bTeff high, T-effector signature score greater than or equal to 1.91; Teff
low, T-effector signature score less than 1.91.
cTC3 or IC3 (high) ¼ PD-L1 expression on greater than or equal to 50% of TC
or greater than or equal to 10% of IC; TC2/3 or IC2/3 ¼ PD-L1 expression on
greater than or equal to 5% of TC or IC; TC1/2/3 or IC1/2/3 (positive) ¼ PD-
L1 expression on greater than or equal to 1% of TC or IC; TC1/2 or IC1/2
(low) ¼ PD-L1 expression on greater than or equal to 1% of TC or IC and less
than 50% of TC and less than 10% of IC; TC0 and IC0 (negative) 1/4 PD-L1
expression on less than 1% of TC and IC.
AþCnP, atezolizumabþcarboplatinþnab-paclitaxel; CCOD, clinical cutoff
date; CI, confidence interval; CnP, carboplatinþnab-paclitaxel; HR, hazard
ratio; IC, tumor-infiltrating immune cells; ITT, intention-to-treat; OS,
overall survival; PD-L1, programmed death-ligand 1; TC, tumor cells; Teff, T-
effector.
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AþCnP, 12.3%; CnP, 6.6%), particularly pneumonitis
(AþCP, 3.3%; AþCnP, 3.0%; CnP, 0.6%), and by blood
and lymphatic system disorders (AþCP, 6.9%; AþCnP,
7.2%; CnP, 3.9%), mainly febrile neutropenia (AþCP,
4.8%; AþCnP, 3.9%; CnP, 1.5%) and anemia (AþCP,
1.8%; AþCnP, 2.1%; CnP, 0.9%). AEs led to withdrawal
of any treatment in 88 patients (26.5%) in the AþCP
arm, 102 patients (30.5%) in the AþCnP arm, and 58
patients (17.4%) in the CnP arm.
Treatment-related AEs (TRAEs) of any grade
occurred in 306 patients (92.2%) in the AþCP arm, 316
patients (94.6%) in the AþCnP arm, and 303 patients
(90.7%) in the CnP arm (Tables 4 and 5). The most
common grade 3 and 4 TRAEs (10% incidence in any
arm) were anemia (AþCP, 9.3%; AþCnP, 22.2%; CnP,
20.7%), neutropenia (AþCP, 7.5%; AþCnP, 21.3%; CnP,
22.5%), febrile neutropenia (AþCP, 7.5%; AþCnP, 5.4%;
CnP, 2.1%), thrombocytopenia (AþCP, 4.2%; AþCnP,
9.3%; CnP, 8.1%), and decreased neutrophil count
(AþCP, 4.8%; AþCnP, 10.8%; CnP, 13.8%) (Table 5).
Serious TRAEs occurred in 77 patients (23.2%) in the
AþCP arm, 70 patients (21.0%) in the AþCnP arm, and
35 patients (10.5%) in the CnP arm (Table 4 and
Supplementary Table 4). The most common grade 3 and
4 serious TRAEs (2% incidence in any arm) were febrile
neutropenia (AþCP, 4.5%; AþCnP, 3.9%; CnP, 1.5%) and
pneumonitis (AþCP, 2.4%; AþCnP, 0.9%; CnP, 0.6%)(Supplementary Table 4). Nine patients (2.7%) in the AþCP
arm, four patients (1.2%) in the AþCnP arm, and three
patients (0.9%) in the CnP arm had treatment-related grade
5 AEs (Supplementary Table 5).
Most immune-related AEs were grade 1 and 2 in all
the treatment arms. The most common immune-related
AEs (5% incidence in any arm) were rash (AþCP,
24.7%; AþCnP, 23.1%; CnP, 11.7%), abnormal hepatic
function (AþCP, 16.9%; AþCnP, 17.7%; CnP, 8.1%),
hypothyroidism (AþCP, 10.5%; AþCnP, 11.1%; CnP,
0.9%), and pneumonitis (AþCP, 7.5%; AþCnP, 7.5%;
CnP, 1.5%) (Supplementary Table 6). Two patients in the
AþCP arm experienced a grade 5 immune-related AE:
one case of Guillain-Barré syndrome and one of pneu-
monitis. In the AþCnP arm, one patient had a grade 5
immune-related AE of abnormal hepatic function.
Discussion
IMpower131 met its coprimary end point of
investigator-assessed PFS in the ITT population (median
PFS: AþCnP, 6.3 mo versus CnP, 5.6 mo; stratified HR ¼
0.71; 95% CI: 0.60–0.85; p ¼ 0.0001), and an enhanced
PFS benefit was observed with AþCnP versus CnP in the
PD-L1–high subgroup (TC3 or IC3), despite not being
formally tested for treatment comparison. Median OS in
the ITT population was similar between the AþCnP
(14.2 mo) and CnP (13.5 mo) arms (stratified HR ¼ 0.88,
95% CI: 0.73–1.05; p ¼ 0.1581). Of note, a higher
Table 4. Safety Summarya
AþCP (n ¼ 332) AþCnP (n ¼ 334) CnP (n ¼ 334)
Median treatment duration (range), mo
Atezolizumab 5.5 (0–37) 6.7 (0–37) NA
Carboplatin 2.2 (0–5) 2.6 (0–7) 2.4 (0–7)
Nab-paclitaxel NA 3.0 (0–7) 2.8 (0–7)
Paclitaxel 2.2 (0–5) NA NA
All-cause AE, n (%) 325 (97.9) 332 (99.4) 324 (97.0)
Grade 3–4 185 (55.7) 243 (72.8) 221 (66.2)
Grade 5 28 (8.4) 34 (10.2) 14 (4.2)
Treatment-related AE, n (%)b 306 (92.2) 316 (94.6) 303 (90.7)
Grade 3–4 146 (44.0) 227 (68.0) 192 (57.5)
Grade 5 9 (2.7) 4 (1.2) 3 (0.9)
Serious AE, n (%) 143 (43.1) 160 (47.9) 96 (28.7)
Treatment-related, n (%)b 77 (23.2) 70 (21.0) 35 (10.5)
AE leading to withdrawal from any treatment, n (%)b 88 (26.5) 102 (30.5) 58 (17.4)
AE leading to any dose modification/interruption, n (%)b 188 (56.6) 261 (78.1) 219 (65.6)
aCCOD: October 3, 2018.
bIncidence of treatment-related AEs, serious treatment-related AEs, and AEs leading to withdrawal from any treatment or any dose modification/interruption
are for any study treatment.
AþCnP, atezolizumabþcarboplatinþnab-paclitaxel; AþCP, atezolizumabþcarboplatinþpaclitaxel; AE, adverse event; CCOD, clinical cutoff date; CnP,
carboplatinþnab-paclitaxel; NA, not applicable.
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quent cancer immunotherapy than patients in the
AþCnP arm. Although patients with low PD-L1 expres-
sion (TC1/2 or IC1/2) appeared to derive PFS benefit
with the addition of atezolizumab (HR ¼ 0.70, 95% CI:Table 5. TRAEs (Greater Than or Equal to 10% Incidence for A
Patients, n (%)
AþCP (n ¼ 332) Aþ
Grade 1–2 Grade 3–4 Grade 5 Gr
Anemia 87 (26.2) 31 (9.3) 0 95
Alopecia 128 (38.6) 0 0 11
Neutropenia 19 (5.7) 25 (7.5) 0 45
Nausea 71 (21.4) 3 (0.9) 0 10
Fatigue 72 (21.7) 8 (2.4) 0 60
Thrombocytopenia 32 (9.6) 14 (4.2) 0 55
Decreased appetite 70 (21.1) 2 (0.6) 0 52
Diarrhea 58 (17.5) 6 (1.8) 0 53
Asthenia 48 (14.5) 10 (3.0) 0 38
Decreased platelet count 31 (9.3) 7 (2.1) 0 40
Decreased neutrophil count 3 (0.9) 16 (4.8) 0 21
Constipation 44 (13.3) 0 0 51
Peripheral neuropathy 58 (17.5) 7 (2.1) 0 30
Peripheral sensory neuropathy 52 (15.7) 2 (0.6) 0 41
Vomiting 34 (10.2) 1 (0.3) 0 41
Hypomagnesemia 20 (6.0) 0 0 33
Leukopenia 6 (1.8) 2 (0.6) 0 22
Decreased WBC count 6 (1.8) 6 (1.8) 0 15
Arthralgia 44 (13.3) 1 (0.3) 0 20
Rash 33 (9.9) 2 (0.6) 0 25
Myalgia 35 (10.5) 0 0 14
Febrile neutropenia 0 25 (7.5) 0 0
aCCOD: October 3, 2018.
AþCnP, atezolizumabþcarboplatinþnab-paclitaxel; AþCP, atezolizumabþcar
paclitaxel; TRAE, treatment-related adverse event; WBC, white blood cell.0.54–0.91), this observation did not translate into an OS
benefit (HR ¼ 1.08, 95% CI: 0.81–1.45) in the AþCnP
versus CnP arms in this subgroup and likely contributed
to the non-significant OS result in the ITT population.
This observation of OS in the PD-L1–low subgroup wasny Grade, Greater Than 5% Incidence for Grades 3–5)a
CnP (n ¼ 334) CnP (n ¼ 334)
ade 1–2 Grade 3–4 Grade 5 Grade 1–2 Grade 3–4 Grade 5
(28.4) 74 (22.2) 0 110 (32.9) 69 (20.7) 0
1 (33.2) 0 0 100 (29.9) 0 0
(13.5) 71 (21.3) 0 45 (13.5) 75 (22.5) 0
6 (31.7) 7 (2.1) 0 88 (26.4) 2 (0.6) 0
(18.0) 13 (3.9) 0 66 (19.8) 7 (2.1) 0
(16.5) 31 (9.3) 0 61 (18.3) 27 (8.1) 0
(15.6) 10 (3.0) 0 62 (18.6) 3 (0.9) 0
(15.9) 10 (3.0) 0 56 (16.8) 7 (2.1) 0
(11.4) 7 (2.1) 0 44 (13.2) 9 (2.7) 0
(12.0) 15 (4.5) 0 38 (11.4) 20 (6.0) 0
(6.3) 36 (10.8) 0 19 (5.7) 46 (13.8) 0
(15.3) 0 0 38 (11.4) 1 (0.3) 0
(9.0) 4 (1.2) 0 30 (9.0) 2 (0.6) 0
(12.3) 4 (1.2) 0 29 (8.7) 1 (0.3) 0
(12.3) 3 (0.9) 0 39 (11.7) 1 (0.3) 0
(9.9) 5 (1.5) 0 24 (7.2) 2 (0.6) 0
(6.6) 20 (6.0) 0 20 (6.0) 14 (4.2) 0
(4.5) 14 (4.2) 0 22 (6.6) 14 (4.2) 0
(6.0) 0 0 11 (3.3) 0 0
(7.5) 2 (0.6) 0 10 (3.0) 1 (0.3) 0
(4.2) 0 0 15 (4.5) 0 0
18 (5.4) 0 0 7 (2.1) 0
boplatinþpaclitaxel; CCOD, clinical cutoff date; CnP, carboplatinþnab-
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tigate whether an imbalance in patients’ prognostic fac-
tors between arms in this subgroup could have
contributed to this finding. Patients with high PD-L1
expression (TC3 or IC3) appeared to derive an OS
benefit with the addition of atezolizumab (HR ¼ 0.48,
95% CI: 0.29–0.81). Although this was encouraging, any
conclusions are limited, as the study was not powered
for this subgroup analysis. The treatment effect in pa-
tients with high PD-L1 expression observed in
IMpower131 is consistent with previous reports of ate-
zolizumab single or combination therapy in both first-
and second-line settings of NSCLC, as reported in POP-
LAR, OAK, IMpower150, and the interim analysis of
IMpower110.6,7,9,14,18
The study KEYNOTE-407 investigated pem-
brolizumab in combination with carboplatin and either
paclitaxel or nab-paclitaxel or chemotherapy alone in
patients with stage IV squamous NSCLC who had not
received previous systemic therapy for metastatic dis-
ease.4 The addition of pembrolizumab to the chemo-
therapy regimen resulted in significant improvements in
PFS and OS in the ITT population. As cancer immuno-
therapy is established as the standard of care in NSCLC,
future prospective trials may address the question of
whether programmed cell death protein 1 inhibition or
PD-L1 inhibition results in favorable treatment out-
comes, as cross-trial comparisons are inherently limited
owing to the risk of systematic bias and confounding
factors.
The safety profile in IMpower131 was consistent
with the known safety profile of each individual treat-
ment, and no new safety signals were observed. Serious
AEs, serious TRAEs, and AEs leading to withdrawal from
any treatment were higher in the atezolizumab-
containing arms than in the chemotherapy-alone arm.
The higher incidence of serious AEs observed in the
AþCP and AþCnP arms than that observed in the CnP
arm may be attributed to febrile neutropenia, anemia,
and pneumonitis, a known risk with atezolizumab.
In conclusion, IMpower131 suggests that addition of
atezolizumab to CnP provides PFS and OS benefit in
patients with metastatic squamous NSCLC whose tumors
have high PD-L1 expression.
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